A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment

Colitis-associated colon cancer (CAC) is a widely recognized cancer, while treatment with the existing chemotherapeutic drugs affords limited clinical benefits. Herein we proposed a site-specific, combination nanotherapy strategy for targeted treatment of CAC by the oral route. : A reactive oxygen s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Theranostics 2019-01, Vol.9 (13), p.3732-3753
Hauptverfasser: Zhang, Qixiong, Zhang, Fuzhong, Li, Shanshan, Liu, Renfeng, Jin, Taotao, Dou, Yin, Zhou, Zhenhua, Zhang, Jianxiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3753
container_issue 13
container_start_page 3732
container_title Theranostics
container_volume 9
creator Zhang, Qixiong
Zhang, Fuzhong
Li, Shanshan
Liu, Renfeng
Jin, Taotao
Dou, Yin
Zhou, Zhenhua
Zhang, Jianxiang
description Colitis-associated colon cancer (CAC) is a widely recognized cancer, while treatment with the existing chemotherapeutic drugs affords limited clinical benefits. Herein we proposed a site-specific, combination nanotherapy strategy for targeted treatment of CAC by the oral route. : A reactive oxygen species (ROS)-responsive and hydrogen peroxide-eliminating material OCD was synthesized, which was further produced into a functional nanoparticle (OCD NP). The antioxidative stress and anti-inflammatory effects of OCD NP were examined by and experiments. By packaging an anticancer drug camptothecin-11 (CPT-11) into OCD NP, a ROS-responsive nanotherapy CPT-11/OCD NP was obtained, and its antitumor activity was evaluated by both and studies. Preliminary safety studies were also performed for CPT-11/OCD NP in mice. : OCD NP significantly attenuated oxidative stress and inhibited inflammatory response in different cells and mice with induced colitis. CPT-11/OCD NP could selectively release drug molecules under intestinal pH conditions and at high levels of ROS. In C26 murine colon carcinoma cells, this nanotherapy showed significantly higher antitumor activity compared to free CPT-11 and a non-responsive CPT-11 nanotherapy. Correspondingly, oral delivery of CPT-11/OCD NP notably inhibited tumorigenesis and tumor growth in mice with induced CAC. By combination therapy with the nanovehicle OCD NP in the inflammatory phase, more desirable therapeutic effects were achieved. Furthermore, CPT-11/OCD NP displayed excellent safety profile for oral administration at a dose that is 87.3-fold higher than that employed in therapeutic studies. : Anticancer nanotherapies derived from intrinsic anti-inflammatory nanocarriers are promising for targeted combination treatment of inflammation-associated tumors by simultaneously shaping pro-inflammatory microenvironment toward a relatively normal niche sensitive to chemotherapy.
doi_str_mv 10.7150/thno.34377
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6587349</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31281510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-28451e391b27170aba9a8e077ee978fd8351d7f0dca032dc14dfe2eeaa53f03c3</originalsourceid><addsrcrecordid>eNpVkd9LwzAQx4Mobsy9-AdInoXNpGmX9EUYw1-wKeh8Lrf2skXaZKTpsP-9ndOh93IHd_f5Hvcl5JKzseQJuwkb68YiFlKekD5XQo3kJGanf-oeGdb1B-siZlHK03PSEzxSPOGsTz6ndNGUwejG5sE4CyV9BuvCBj1sW6qdp0vwawxY0KVHCBXaQJ2mM1c6S2dgc_R01dI3U3UcsOiaumzpK66bEoKxa7psqo6yMLl3aHfGO7tnXJAzDWWNw588IO_3d8vZ42j-8vA0m85HuZAqjCIVJxxFyleR5JLBClJQyKRETKXShRIJL6RmRQ5MREXO40JjhAiQCM1ELgbk9sDdNqsKi7yT9lBmW28q8G3mwGT_O9ZssrXbZZNESRGnHeD6AOjur2uP-rjLWba3INtbkH1b0A1f_VU7jv4-XHwBn4WG7Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Zhang, Qixiong ; Zhang, Fuzhong ; Li, Shanshan ; Liu, Renfeng ; Jin, Taotao ; Dou, Yin ; Zhou, Zhenhua ; Zhang, Jianxiang</creator><creatorcontrib>Zhang, Qixiong ; Zhang, Fuzhong ; Li, Shanshan ; Liu, Renfeng ; Jin, Taotao ; Dou, Yin ; Zhou, Zhenhua ; Zhang, Jianxiang</creatorcontrib><description>Colitis-associated colon cancer (CAC) is a widely recognized cancer, while treatment with the existing chemotherapeutic drugs affords limited clinical benefits. Herein we proposed a site-specific, combination nanotherapy strategy for targeted treatment of CAC by the oral route. : A reactive oxygen species (ROS)-responsive and hydrogen peroxide-eliminating material OCD was synthesized, which was further produced into a functional nanoparticle (OCD NP). The antioxidative stress and anti-inflammatory effects of OCD NP were examined by and experiments. By packaging an anticancer drug camptothecin-11 (CPT-11) into OCD NP, a ROS-responsive nanotherapy CPT-11/OCD NP was obtained, and its antitumor activity was evaluated by both and studies. Preliminary safety studies were also performed for CPT-11/OCD NP in mice. : OCD NP significantly attenuated oxidative stress and inhibited inflammatory response in different cells and mice with induced colitis. CPT-11/OCD NP could selectively release drug molecules under intestinal pH conditions and at high levels of ROS. In C26 murine colon carcinoma cells, this nanotherapy showed significantly higher antitumor activity compared to free CPT-11 and a non-responsive CPT-11 nanotherapy. Correspondingly, oral delivery of CPT-11/OCD NP notably inhibited tumorigenesis and tumor growth in mice with induced CAC. By combination therapy with the nanovehicle OCD NP in the inflammatory phase, more desirable therapeutic effects were achieved. Furthermore, CPT-11/OCD NP displayed excellent safety profile for oral administration at a dose that is 87.3-fold higher than that employed in therapeutic studies. : Anticancer nanotherapies derived from intrinsic anti-inflammatory nanocarriers are promising for targeted combination treatment of inflammation-associated tumors by simultaneously shaping pro-inflammatory microenvironment toward a relatively normal niche sensitive to chemotherapy.</description><identifier>ISSN: 1838-7640</identifier><identifier>EISSN: 1838-7640</identifier><identifier>DOI: 10.7150/thno.34377</identifier><identifier>PMID: 31281510</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Research Paper</subject><ispartof>Theranostics, 2019-01, Vol.9 (13), p.3732-3753</ispartof><rights>Ivyspring International Publisher 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-28451e391b27170aba9a8e077ee978fd8351d7f0dca032dc14dfe2eeaa53f03c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587349/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587349/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31281510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Qixiong</creatorcontrib><creatorcontrib>Zhang, Fuzhong</creatorcontrib><creatorcontrib>Li, Shanshan</creatorcontrib><creatorcontrib>Liu, Renfeng</creatorcontrib><creatorcontrib>Jin, Taotao</creatorcontrib><creatorcontrib>Dou, Yin</creatorcontrib><creatorcontrib>Zhou, Zhenhua</creatorcontrib><creatorcontrib>Zhang, Jianxiang</creatorcontrib><title>A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment</title><title>Theranostics</title><addtitle>Theranostics</addtitle><description>Colitis-associated colon cancer (CAC) is a widely recognized cancer, while treatment with the existing chemotherapeutic drugs affords limited clinical benefits. Herein we proposed a site-specific, combination nanotherapy strategy for targeted treatment of CAC by the oral route. : A reactive oxygen species (ROS)-responsive and hydrogen peroxide-eliminating material OCD was synthesized, which was further produced into a functional nanoparticle (OCD NP). The antioxidative stress and anti-inflammatory effects of OCD NP were examined by and experiments. By packaging an anticancer drug camptothecin-11 (CPT-11) into OCD NP, a ROS-responsive nanotherapy CPT-11/OCD NP was obtained, and its antitumor activity was evaluated by both and studies. Preliminary safety studies were also performed for CPT-11/OCD NP in mice. : OCD NP significantly attenuated oxidative stress and inhibited inflammatory response in different cells and mice with induced colitis. CPT-11/OCD NP could selectively release drug molecules under intestinal pH conditions and at high levels of ROS. In C26 murine colon carcinoma cells, this nanotherapy showed significantly higher antitumor activity compared to free CPT-11 and a non-responsive CPT-11 nanotherapy. Correspondingly, oral delivery of CPT-11/OCD NP notably inhibited tumorigenesis and tumor growth in mice with induced CAC. By combination therapy with the nanovehicle OCD NP in the inflammatory phase, more desirable therapeutic effects were achieved. Furthermore, CPT-11/OCD NP displayed excellent safety profile for oral administration at a dose that is 87.3-fold higher than that employed in therapeutic studies. : Anticancer nanotherapies derived from intrinsic anti-inflammatory nanocarriers are promising for targeted combination treatment of inflammation-associated tumors by simultaneously shaping pro-inflammatory microenvironment toward a relatively normal niche sensitive to chemotherapy.</description><subject>Research Paper</subject><issn>1838-7640</issn><issn>1838-7640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkd9LwzAQx4Mobsy9-AdInoXNpGmX9EUYw1-wKeh8Lrf2skXaZKTpsP-9ndOh93IHd_f5Hvcl5JKzseQJuwkb68YiFlKekD5XQo3kJGanf-oeGdb1B-siZlHK03PSEzxSPOGsTz6ndNGUwejG5sE4CyV9BuvCBj1sW6qdp0vwawxY0KVHCBXaQJ2mM1c6S2dgc_R01dI3U3UcsOiaumzpK66bEoKxa7psqo6yMLl3aHfGO7tnXJAzDWWNw588IO_3d8vZ42j-8vA0m85HuZAqjCIVJxxFyleR5JLBClJQyKRETKXShRIJL6RmRQ5MREXO40JjhAiQCM1ELgbk9sDdNqsKi7yT9lBmW28q8G3mwGT_O9ZssrXbZZNESRGnHeD6AOjur2uP-rjLWba3INtbkH1b0A1f_VU7jv4-XHwBn4WG7Q</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Zhang, Qixiong</creator><creator>Zhang, Fuzhong</creator><creator>Li, Shanshan</creator><creator>Liu, Renfeng</creator><creator>Jin, Taotao</creator><creator>Dou, Yin</creator><creator>Zhou, Zhenhua</creator><creator>Zhang, Jianxiang</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190101</creationdate><title>A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment</title><author>Zhang, Qixiong ; Zhang, Fuzhong ; Li, Shanshan ; Liu, Renfeng ; Jin, Taotao ; Dou, Yin ; Zhou, Zhenhua ; Zhang, Jianxiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-28451e391b27170aba9a8e077ee978fd8351d7f0dca032dc14dfe2eeaa53f03c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Qixiong</creatorcontrib><creatorcontrib>Zhang, Fuzhong</creatorcontrib><creatorcontrib>Li, Shanshan</creatorcontrib><creatorcontrib>Liu, Renfeng</creatorcontrib><creatorcontrib>Jin, Taotao</creatorcontrib><creatorcontrib>Dou, Yin</creatorcontrib><creatorcontrib>Zhou, Zhenhua</creatorcontrib><creatorcontrib>Zhang, Jianxiang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Theranostics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Qixiong</au><au>Zhang, Fuzhong</au><au>Li, Shanshan</au><au>Liu, Renfeng</au><au>Jin, Taotao</au><au>Dou, Yin</au><au>Zhou, Zhenhua</au><au>Zhang, Jianxiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment</atitle><jtitle>Theranostics</jtitle><addtitle>Theranostics</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>9</volume><issue>13</issue><spage>3732</spage><epage>3753</epage><pages>3732-3753</pages><issn>1838-7640</issn><eissn>1838-7640</eissn><abstract>Colitis-associated colon cancer (CAC) is a widely recognized cancer, while treatment with the existing chemotherapeutic drugs affords limited clinical benefits. Herein we proposed a site-specific, combination nanotherapy strategy for targeted treatment of CAC by the oral route. : A reactive oxygen species (ROS)-responsive and hydrogen peroxide-eliminating material OCD was synthesized, which was further produced into a functional nanoparticle (OCD NP). The antioxidative stress and anti-inflammatory effects of OCD NP were examined by and experiments. By packaging an anticancer drug camptothecin-11 (CPT-11) into OCD NP, a ROS-responsive nanotherapy CPT-11/OCD NP was obtained, and its antitumor activity was evaluated by both and studies. Preliminary safety studies were also performed for CPT-11/OCD NP in mice. : OCD NP significantly attenuated oxidative stress and inhibited inflammatory response in different cells and mice with induced colitis. CPT-11/OCD NP could selectively release drug molecules under intestinal pH conditions and at high levels of ROS. In C26 murine colon carcinoma cells, this nanotherapy showed significantly higher antitumor activity compared to free CPT-11 and a non-responsive CPT-11 nanotherapy. Correspondingly, oral delivery of CPT-11/OCD NP notably inhibited tumorigenesis and tumor growth in mice with induced CAC. By combination therapy with the nanovehicle OCD NP in the inflammatory phase, more desirable therapeutic effects were achieved. Furthermore, CPT-11/OCD NP displayed excellent safety profile for oral administration at a dose that is 87.3-fold higher than that employed in therapeutic studies. : Anticancer nanotherapies derived from intrinsic anti-inflammatory nanocarriers are promising for targeted combination treatment of inflammation-associated tumors by simultaneously shaping pro-inflammatory microenvironment toward a relatively normal niche sensitive to chemotherapy.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>31281510</pmid><doi>10.7150/thno.34377</doi><tpages>22</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1838-7640
ispartof Theranostics, 2019-01, Vol.9 (13), p.3732-3753
issn 1838-7640
1838-7640
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6587349
source PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Research Paper
title A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Multifunctional%20Nanotherapy%20for%20Targeted%20Treatment%20of%20Colon%20Cancer%20by%20Simultaneously%20Regulating%20Tumor%20Microenvironment&rft.jtitle=Theranostics&rft.au=Zhang,%20Qixiong&rft.date=2019-01-01&rft.volume=9&rft.issue=13&rft.spage=3732&rft.epage=3753&rft.pages=3732-3753&rft.issn=1838-7640&rft.eissn=1838-7640&rft_id=info:doi/10.7150/thno.34377&rft_dat=%3Cpubmed_cross%3E31281510%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31281510&rfr_iscdi=true